Navigation Links
Positive Results Using Affitech-Identified Human Antibody That,Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model,Reported by Peregrine

OSLO, Norway--(BUSINESS WIRE)--Apr 23, 2007 - Affitech AS, the human antibody therapeutics company announced today that Peregrine Pharmaceuticals, Inc. reported positive in vivo test results of R3, a fully human monoclonal antibody developed by Affitech, in a pancreatic cancer model at the recently concluded Centennial Annual Meeting of the American Association for Cancer Research (AACR). R3 has been designed by the two companies for selective blocking of VEGF (vascular endothelial growth factor) binding to VEGF receptor 2, as opposed to other anti-angiogenic agents which block activity of both VEGF receptors.

The R3 antibody, which was generated by Affitech's phagemid antibody library screening method, when tested by Peregrine on a pancreatic cancer model, showed significant reduction of the growth, vascularization and macrophage infiltration of pancreatic tumors in mice. This is the first antibody from Affitech's library that has been tested in a preclinical development model. Peregrine announced that the positive results of R3 antibody support the Company's intent to progress its anti-VEGF program towards clinical trials.

"We are delighted with this in vivo result, " commented Martin Welschof, Ph.D., Chief Executive Officer of Affitech. "Affitech and Peregrine have several collaborative antibody projects. The quality of the antibody and excellent collaborative research by the scientists of our two organizations are contributing to advancing Peregrine's anti-VEGF portfolio. This success also has important implications for accelerating our own human therapeutic antibody program "

Editors notes

Affitech AS is a privately held human therapeutic antibody discovery and development company with headquarters and R&D facilities in Oslo, Norway and its US subsidiary in the San Francisco Bay Area. The Company's current disease focus is oncology and it utilizes two discrete but unique approaches for the discovery of fully human antibodies - (i) Molecule Based Antibody Discovery, and (ii) Cell Based Antibody Discovery. Molecule Based Antibody Discovery involves proprietary PhagemidScreeN and AffiScreeN(TM) technologies and uses validated targets for discovery purpose. Cell Based Antibody Discovery is based on CBAS(TM) technology, which is a "reverse-screening" approach for discovering antibodies and their cognate targets utilizing disease-specific cells. Several of the Company's proprietary product candidates currently in development were generated by CBAS(TM). Affitech also sells its proprietary Protein L product line for the purification of antibody and antibody fragments. Affitech offers collaborators a flexible business model and very competitive price structure with low royalty stacking. The Company has concluded deals with commercial organizations such as Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, Pharmexa and others. Further information at www.affitech.com.

Contact

Affitech (Norway)
Dr. Martin Welschof
Chief Executive Officer
+47 22 95 87 58
m.welschof@affitech.com
or
Affitech (USA)
Dr. Rathin C. Das
President
+ 1 925 935 9803
r.das@affitech.com
or
Media enquiries
Hayhurst Media
Richard Hayhurst
+44 7711 821527
richard@hayhurstmedia.com


'"/>




Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... RADNOR, Pennsylvania , 22 de marzo de ... proveedor independiente global líder de soluciones de productos ... ha anunciado hoy que ha adquirido EPL Archives, ... apoya a los clientes en todo el ciclo ... y comercialización ofreciendo una muestra de archivo, almacenamiento ...
(Date:3/22/2017)... DUBLIN , Mar. 22, 2017 Research ... Care Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 10.9% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... solutions, today reported financial and operational results for ... 31, 2016. 2016 Highlights ... compared to the full year 2015  ... year  Direct-to-consumer model launched in ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Sam ... insurance assistance, financial planning, and related services to residents of the region, is ... awareness of threatened species and wild lands. , Endangered Species International is committed ...
(Date:3/22/2017)... San Jose, CA (PRWEB) , ... March 22, ... ... of San Jose, Santa Cruz and Milpitas with a robust, ongoing community enrichment ... Supportive Housing (FSH), a nonprofit organization which has provided for the critical needs ...
(Date:3/22/2017)... ... 2017 , ... The American Society for Preventive Cardiology ... for prescribers to improve patients’ access to the revolutionary therapy for appropriate patients ... of the article entitled “PCSK9 Inhibitor Access Barriers: Issues and Recommendations: Improving ...
(Date:3/22/2017)... ... March 22, 2017 , ... Old School Labs™, makers of ... Theophane as a new Brand Ambassador. Theophane, who trained with Floyd Mayweather, made his ... 2011. He has racked up an impressive number of wins in contests in Britain, ...
(Date:3/22/2017)... Georgia (PRWEB) , ... March 22, 2017 , ... ... time consuming and frustrating and this tool bypasses that. Healthcare facilities across ... identified an opportunity to offer their clients and hospitals, across the country, an ...
Breaking Medicine News(10 mins):